Trial Profile

Phase I/II clinical study of CTR-107 (Noregen™) for Retinal Diseases

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jul 2023 New trial record
28 Jun 2023 According to an Wacker Biotech media release, Caeregen Therapeutics and Wacker Biotech will collaborate on the development and production of CTR-107 (Noregen™) for the treatment of retinal-related vision loss.
28 Jun 2023 According to an Wacker Biotech media release, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands to support this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com